Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 161

The DOI matches its Crossref record.

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1 R,3 R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1 H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist

Open access
De Savi, Chris, Bradbury, Robert H., Rabow, Alfred A., Norman, Richard A., de Almeida, Camila, Andrews, David M., Ballard, Peter, Buttar, David, Callis, Rowena J., Currie, Gordon S., Curwen, Jon O., Davies, Chris D., Donald, Craig S., Feron, Lyman J. L., Gingell, Helen, Glossop, Steven C., Hayter, Barry R., Hussain, Syeed, Karoutchi, Galith, Lamont, Scott G., MacFaul, Philip, Moss, Thomas A., Pearson, Stuart E., Tonge, Michael, Walker, Graeme E., Weir, Hazel M., Wilson, Zena · 2015 · Journal of Medicinal Chemistry

Abstract

The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equivalent potency and preclinical pharmacology to the intramuscular SERD fulvestrant is described. A directed screen identified the 1-aryl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole motif as a novel, druglike ER ligand. Aided by crystal structures of novel ligands bound to an ER construct, medicinal chemistry iterations led to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (30b, AZD9496), a clinical candidate with high oral bioavailability across preclinical species that is currently being evaluated in phase I clinical trials for the treatment of advanced estrogen receptor (ER) positive breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.5b00984

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 161

Metadata

Authors
De Savi, C., Bradbury, R. H., Rabow, A. A., Norman, R. A., de Almeida, C., Andrews, D. M., Ballard, P., Buttar, D., Callis, R. J., Currie, G. S., Curwen, J. O., Davies, C. D., Donald, C. S., Feron, L. J. L., Gingell, H., Glossop, S. C., Hayter, B. R., Hussain, S., Karoutchi, G., Lamont, S. G., MacFaul, P., Moss, T. A., Pearson, S. E., Tonge, M., Walker, G. E., Weir, H. M., & Wilson, Z.
Venue
Journal of Medicinal Chemistry
Published
2015-10-07
Volume
58
Issue
20
Pages
8128-8140
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2258559299
Cited by
161
References
0
FWCI
8.22
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1 R,3 R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1 H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist. https://app.cochat.ai/papers/10.1021/acs.jmedchem.5b00984
The paper
De Savi, C., Bradbury, R. H., Rabow, A. A., Norman, R. A., de Almeida, C., Andrews, D. M., Ballard, P., Buttar, D., Callis, R. J., Currie, G. S., Curwen, J. O., Davies, C. D., Donald, C. S., Feron, L. J. L., Gingell, H., Glossop, S. C., Hayter, B. R., Hussain, S., Karoutchi, G., . . . Wilson, Z. (2015). Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1 R,3 R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1 H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5b00984

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.